Prescient Therapeutics Ltd (PTX) - Total Liabilities
Based on the latest financial reports, Prescient Therapeutics Ltd (PTX) has total liabilities worth AU$1.51 Million AUD (≈ $1.07 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Prescient Therapeutics Ltd - Total Liabilities Trend (1989–2025)
This chart illustrates how Prescient Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. See PTX working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Prescient Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Prescient Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SRM Entertainment, Inc. Common Stock
NASDAQ:SRM
|
USA | $751.58K |
|
SuperCom Ltd
F:50S
|
Germany | €28.23 Million |
|
Derimod Konfeksiyon Ayakkabi Deri Sanayi ve Ticaret AS
IS:DERIM
|
Turkey | TL254.20 Million |
|
York Timber Holdings Ltd
JSE:YRK
|
South Africa | ZAC1.86 Billion |
|
Full Wang International Development Co Ltd
TWO:6219
|
Taiwan | NT$11.84 Billion |
|
Klotho Neurosciences, Inc.
NASDAQ:KLTO
|
USA | $145.89K |
|
Latitude Tree Holdings Bhd
KLSE:7006
|
Malaysia | RM140.25 Million |
|
Binh Duong Trade and Development JSC
VN:TDC
|
Vietnam | ₫2.83 Trillion |
Liability Composition Analysis (1989–2025)
This chart breaks down Prescient Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Prescient Therapeutics Ltd market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.95 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 7.62 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Prescient Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Prescient Therapeutics Ltd (1989–2025)
The table below shows the annual total liabilities of Prescient Therapeutics Ltd from 1989 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$3.17 Million ≈ $2.25 Million |
+36.50% |
| 2024-06-30 | AU$2.33 Million ≈ $1.65 Million |
+14.40% |
| 2023-06-30 | AU$2.03 Million ≈ $1.44 Million |
+137.49% |
| 2022-06-30 | AU$856.01K ≈ $605.68K |
+58.62% |
| 2021-06-30 | AU$539.68K ≈ $381.86K |
-38.95% |
| 2020-06-30 | AU$883.95K ≈ $625.45K |
+28.89% |
| 2019-06-30 | AU$685.79K ≈ $485.24K |
+24.34% |
| 2018-06-30 | AU$551.56K ≈ $390.26K |
+23.98% |
| 2017-06-30 | AU$444.89K ≈ $314.79K |
-45.91% |
| 2016-06-30 | AU$822.55K ≈ $582.01K |
+86.47% |
| 2015-06-30 | AU$441.13K ≈ $312.13K |
+74.43% |
| 2014-06-30 | AU$252.89K ≈ $178.94K |
-86.32% |
| 2012-06-30 | AU$1.85 Million ≈ $1.31 Million |
+20.53% |
| 2011-06-30 | AU$1.53 Million ≈ $1.09 Million |
+19.02% |
| 2010-06-30 | AU$1.29 Million ≈ $911.86K |
-27.85% |
| 2009-06-30 | AU$1.79 Million ≈ $1.26 Million |
+6.48% |
| 2008-06-30 | AU$1.68 Million ≈ $1.19 Million |
+13.62% |
| 2007-06-30 | AU$1.48 Million ≈ $1.04 Million |
-12.15% |
| 2006-06-30 | AU$1.68 Million ≈ $1.19 Million |
+24.23% |
| 2005-06-30 | AU$1.35 Million ≈ $957.17K |
+164.83% |
| 2004-06-30 | AU$510.81K ≈ $361.43K |
-24.88% |
| 2003-06-30 | AU$680.00K ≈ $481.14K |
+51.64% |
| 2002-06-30 | AU$448.42K ≈ $317.29K |
-32.84% |
| 2001-06-30 | AU$667.73K ≈ $472.46K |
+520.49% |
| 2000-06-30 | AU$107.61K ≈ $76.14K |
-10.10% |
| 1999-06-30 | AU$119.70K ≈ $84.70K |
+93.13% |
| 1998-06-30 | AU$61.98K ≈ $43.85K |
-54.90% |
| 1997-06-30 | AU$137.43K ≈ $97.24K |
+109.17% |
| 1996-06-30 | AU$65.70K ≈ $46.49K |
-97.24% |
| 1995-06-30 | AU$2.38 Million ≈ $1.69 Million |
-57.18% |
| 1994-06-30 | AU$5.57 Million ≈ $3.94 Million |
+11.23% |
| 1993-06-30 | AU$5.00 Million ≈ $3.54 Million |
-11.84% |
| 1992-06-30 | AU$5.67 Million ≈ $4.02 Million |
+4.61% |
| 1991-06-30 | AU$5.42 Million ≈ $3.84 Million |
+0.67% |
| 1990-06-30 | AU$5.39 Million ≈ $3.81 Million |
-1.86% |
| 1989-06-30 | AU$5.49 Million ≈ $3.89 Million |
-- |
About Prescient Therapeutics Ltd
Prescient Therapeutics Limited, a clinical stage oncology company, develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. The company was formerly known as Virax Holdings Limited and changed its name to… Read more